SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: Zepbound® (tirzepatide) for Obstructive Sleep Apnea (OSA)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.		
Member Name:		
Member Sentara #:		
Prescriber Name:		
	Date:	
Office Contact Name:		
Phone Number:	Fax Number:	
NPI #:		
DRUG INFORMATION: Auth	norization may be delayed if incomplete.	
Drug Name/Form/Strength:		
Dosing Schedule:	Length of Therapy:	
Diagnosis:	ICD Code, if applicable:	
Weight (if applicable):	Date weight obtained:	
Recommended Dosage for Obst • Starting dosage of Zepbound for	tructive Sleep Apnea: or all indications is 2.5 mg injected SC once weekly for 4 weeks.	
	r OSA is 10 mg or 15 mg injected SC once weekly	
• The maintenance dosage for	r weight reduction is 5 mg, 10 mg, or 15 mg, injected SC once weekly	
	below all that apply. All criteria must be met for approval. To entation, including lab results, diagnostics, and/or chart notes, must be	
Initial Authorization: 6 month	s	
☐ Member is 18 years of age or of	lder	
☐ The medication is prescribed by specialist	y an otolaryngologist (ENT), neurologist, pulmonologist or sleep apnea	
☐ The requesting provider is man	aging the member's obstructive sleep apnea	

(Continued on next page)

	Member has a diagnosis of moderate to severe obstructive sleep apnea (OSA) defined by an apnea-hypopnea index \geq 15 events/hour confirmed by polysomnography
	Member is currently on or has tried, failed or unable to tolerate continuous positive airway pressure therapy (CPAP) (an adequate trial is defined as CPAP use for \geq 4 hours per night on \geq 70% of nights for two or more months)
	If unable to tolerate CPAP therapy, please explain the intolerance below:
	Member has a body mass index (BMI) of $\geq 30 \text{kg/m}2$
	Member must have participated in a weight loss treatment plan (e.g. nutritional counseling, an exercise regimen, and calorie restricted/fat restricted diet) in the past 6 months and will continue to follow this treatment plan while taking an anti-obesity medication for obstructive sleep apnea
	Member does NOT have craniofacial abnormalities that may affect breathing
	Member does NOT have diagnosis of central or mixed sleep apnea or Cheyne-Stokes respiration
	Member is NOT using any other GLP-1 product
	Member does NOT have pancreatitis, acute suicidal behavior/ideation, gastroparesis or using prokinetic drugs (i.e metoclopramide), personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2 syndrome
	Documentation submitted:
	□ Polysomnography conducted within the last 12 months
	☐ Weight loss treatment plan within the past 6 months
appro	uthorization: up to 12 months. Check below all that apply. All criteria must be met for oval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart, must be provided or request may be denied.
	Member continues to meet the criteria
	Member is being treated with a maintenance dosage of the requested drug
	Documentation that the member has experienced improvement in OSA symptoms
*:	*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *